JP2003522160A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003522160A5 JP2003522160A5 JP2001557602A JP2001557602A JP2003522160A5 JP 2003522160 A5 JP2003522160 A5 JP 2003522160A5 JP 2001557602 A JP2001557602 A JP 2001557602A JP 2001557602 A JP2001557602 A JP 2001557602A JP 2003522160 A5 JP2003522160 A5 JP 2003522160A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- pharmaceutical composition
- vector
- acid sequence
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical group 0.000 description 30
- 239000008194 pharmaceutical composition Substances 0.000 description 28
- 239000013598 vector Substances 0.000 description 25
- 238000000034 method Methods 0.000 description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 description 21
- 239000013604 expression vector Substances 0.000 description 21
- 239000004037 angiogenesis inhibitor Substances 0.000 description 15
- 241000701161 unidentified adenovirus Species 0.000 description 15
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 13
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000000508 neurotrophic effect Effects 0.000 description 10
- 210000001508 eye Anatomy 0.000 description 8
- 102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 description 7
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 7
- 239000012634 fragment Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 239000002870 angiogenesis inducing agent Substances 0.000 description 3
- 230000001772 anti-angiogenic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 208000007135 Retinal Neovascularization Diseases 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18174300P | 2000-02-11 | 2000-02-11 | |
| US60/181,743 | 2000-02-11 | ||
| US09/599,997 US6821775B1 (en) | 2000-02-11 | 2000-06-23 | Viral vector encoding pigment epithelium-derived factor |
| US09/599,997 | 2000-06-23 | ||
| US22833700P | 2000-08-28 | 2000-08-28 | |
| US60/228,337 | 2000-08-28 | ||
| PCT/US2001/004203 WO2001058494A2 (en) | 2000-02-11 | 2001-02-09 | Gene therapy for treating ocular-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003522160A JP2003522160A (ja) | 2003-07-22 |
| JP2003522160A5 true JP2003522160A5 (https=) | 2008-04-10 |
Family
ID=27391455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001557602A Pending JP2003522160A (ja) | 2000-02-11 | 2001-02-09 | 眼関連疾患の治療のための遺伝子治療 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1253948A2 (https=) |
| JP (1) | JP2003522160A (https=) |
| AU (1) | AU780634C (https=) |
| CA (1) | CA2398571A1 (https=) |
| WO (1) | WO2001058494A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7470659B2 (en) | 2001-12-07 | 2008-12-30 | The Regents Of The University Of California | Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM) |
| JP2006516027A (ja) * | 2002-12-02 | 2006-06-15 | ジェンベク、インコーポレイティッド | 眼関連障害の治療用材料および治療方法 |
| US20040166091A1 (en) | 2003-02-24 | 2004-08-26 | Genvec, Inc. | Materials and methods for treating disorders of the ear |
| WO2006054278A2 (en) | 2004-11-16 | 2006-05-26 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Variants of pigment epithelium derived factor and uses thereof |
| WO2006123248A2 (en) * | 2005-04-18 | 2006-11-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject |
| JP2007291009A (ja) * | 2006-04-25 | 2007-11-08 | Seitai Shigen Laboratory Inc | 血管内膜肥厚抑制剤 |
| WO2009126894A2 (en) * | 2008-04-11 | 2009-10-15 | Massachusetts Eye And Ear Infirmary | Methods and compositions for the diagnosis and treatment of angiogenic disorders |
| CN104619727B (zh) * | 2012-06-25 | 2019-04-05 | 布里格姆及妇女医院股份有限公司 | 靶向治疗 |
| US9790264B2 (en) | 2012-06-25 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compounds and methods for modulating pharmacokinetics |
| ES2667209T3 (es) * | 2013-03-14 | 2018-05-10 | Asklepios Biopharmaceutical, Inc. | Genes del receptor-1 de VEGF soluble modificado y vectores para terapia génica |
| TWI710635B (zh) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
| US12305185B2 (en) | 2018-01-23 | 2025-05-20 | Mount Spec Investments Pty Ltd | Expression vector and method |
| US10632211B2 (en) | 2018-06-11 | 2020-04-28 | The Regents Of The University Of California | Demethylation to treat eye disease |
| CN112566622A (zh) * | 2018-06-19 | 2021-03-26 | 细胞疗法有限责任公司 | 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统 |
| WO2019246141A1 (en) | 2018-06-19 | 2019-12-26 | Cella Therapeutics, Llc | DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-α (TNF-α) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE |
| CN118767143A (zh) | 2019-12-12 | 2024-10-15 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| US20230094423A1 (en) * | 2019-12-18 | 2023-03-30 | Cella Therapeutics, Llc | Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-alpha (tnf-alpha) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319687B1 (en) * | 1992-09-24 | 2001-11-20 | The United States Of America As Represented By The Department Of Health And Human Services | Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene |
| US5840686A (en) * | 1992-09-24 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use |
| US5461749A (en) * | 1994-05-31 | 1995-10-31 | Minnesota Mining And Manufacturing Company | Floor mop and cleaning system |
| US5904144A (en) * | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
| CA2298018C (en) * | 1997-07-23 | 2008-12-16 | Northwestern University | Methods and compositions for inhibiting angiogenesis |
| JP2001517455A (ja) * | 1997-09-23 | 2001-10-09 | ジェンベク、インコーポレイティッド | 真核生物ウイルスベクター構築用プラスミド |
| WO1999026480A1 (en) * | 1997-11-20 | 1999-06-03 | Genetix Pharmaceuticals, Inc. | Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases |
| AU3755900A (en) * | 1999-03-15 | 2000-10-04 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
-
2001
- 2001-02-09 JP JP2001557602A patent/JP2003522160A/ja active Pending
- 2001-02-09 EP EP01909022A patent/EP1253948A2/en not_active Withdrawn
- 2001-02-09 AU AU36818/01A patent/AU780634C/en not_active Ceased
- 2001-02-09 CA CA002398571A patent/CA2398571A1/en not_active Abandoned
- 2001-02-09 WO PCT/US2001/004203 patent/WO2001058494A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peng et al. | Subretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases | |
| JP2003522160A5 (https=) | ||
| Bandello et al. | Pathophysiology and treatment of diabetic retinopathy | |
| Tyagi et al. | Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab | |
| Moshfeghi et al. | Micro-and nanoparticulates | |
| US20030045498A1 (en) | Materials and methods for treating ocular-related disorders | |
| US20080132464A1 (en) | Selective induction of apoptosis to treat ocular disease | |
| RU2519739C2 (ru) | Офтальмологическое фармацевтические композиции для неоангиогенных патологий глаза | |
| JP2017061467A5 (https=) | ||
| US20090041759A1 (en) | Materials and methods for treating ocular-related disorders | |
| JP7730816B2 (ja) | 過剰血管新生に関連する眼疾患を治療する化合物 | |
| Thanos et al. | Delivery of neurotrophic factors and therapeutic proteins for retinal diseases | |
| WO2008137066A1 (en) | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases | |
| US20100129435A1 (en) | Methods and compositions for treatment of ocular neovascularization and neural injury | |
| CN109996814B (zh) | 多激酶抑制剂及在眼部纤维化中的用途 | |
| Zhang et al. | An update on novel ocular nanosystems with possible benefits in the treatment of corneal neovascularization | |
| AU780634B2 (en) | Gene Therapy for treating ocular-related disorders | |
| US20090149381A1 (en) | Methods of regulating angiogenesis through stabilization of PEDF | |
| Wang et al. | Nanomedicine in ophthalmology: conquering anatomical barriers and enhancing therapeutic efficacy | |
| Kuo et al. | Inhibition of corneal neovascularization with plasmid pigment epithelium-derived factor (p-PEDF) delivered by synthetic amphiphile INTeraction-18 (SAINT-18) vector in an experimental model of rat corneal angiogenesis | |
| Truong et al. | Emerging therapeutic approaches in the management of retinal angiogenesis and edema | |
| Khan et al. | Ocular drug delivery: introduction and fundamental concept | |
| Miller et al. | Lack of beneficial effect of intensive topical steroids and beta irradiation of eyes undergoing repeat trabeculectomy | |
| EP1740218A1 (en) | Materials for treating vascular leakage in the eye | |
| US20030170209A1 (en) | Use of a vector comprising a nucleic acid coding for an anti-angiogenic factor for treating corneal neovascularization |